Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon

Multiple Sclerosis

Volumn 14, Issue 5, 2008, Pages 636-639

  Bosca, Isabel ^a   Coret, F ^b   Valero, C ^a   Pascual, A M ^a   Magraner, M J ^a   Landete, L ^a   Casanova, B ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Beta interferon; Disability progression; Multiple sclerosis; Relapses

Indexed keywords

BETA INTERFERON;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PROBABILITY; RECURRENCE RISK; REGRESSION ANALYSIS; RELAPSE; SEX RATIO; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION; UNIVARIATE ANALYSIS;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TREATMENT OUTCOME;

EID: 46849107494     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507086666     Document Type: Article

References (14)

1. Rudick, RA, Lee, J, Simon, J, Ransohoff, RM, Fisher, E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
2. Polman, CH, O'Connor, PW, Havrdova, E, Hutchinson, M, Kappos, L, Miller, DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
3. Hartung, HP, Gonsette, R, Konig, N, Kwiecinski, H, Guseo, A, Morrissey, SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
4. Rio, J, Nos, C, Tintoré, M, Téllez, N, Galán, I, Pelayo, R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
5. Confavreux, C, Vukusic, M, Moreau, T, Adeleine, P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
6. The IFNB multiple sclerosis group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1993; 43: 655-661.
7. Dubois, BD, Keenan, E, Porter, BE, Kapoor, R, Rudge, P, Thompson, AJ, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003; 74: 946-949.
8. Liu, C, Blumhardt, LD. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Mult Scler 1999; 5: 22-28.
9. Sorensen, PS, Ross, C, Clemmesen, KM, Bendtzen, K, Frederiksen, JL, Jensen, K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
10. Sorensen, PS, Deisenhammer, F, Duda, P, Hohlfeld, R, Myhr, KM, Palace, J, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
11. Confavreux, C, Vukusic, S, Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782.
12. Rudick, RA, Lee, JC, Simon, J, Ransohoff, RM, Fisher, E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
13. Waubant, E, Vukusic, S, Gignoux, L, Durand-Dubief, F, Achiti, I, Blanc, S, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61:184-189.
14. O'Rourke, K, Walsh, C, Antonelli, G, Hutchinson, M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342.